Dr. Soheila Azghadi, MD

Dr. Azghadi practices at Meridian Park Radiation Oncolog Center, Inc in Tualatin, Oregon.

Dr. Azghadi's NPI, 1952794455, was assigned on March 9, 2015. Dr. Azghadi graduated from UC Davis School of Medicine in 2017. Dr. Azghadi holds California license A157410.

Dr. Azghadi's primary practice is Meridian Park Radiation Oncolog Center, Inc, at 6489 SW Borland Rd, Tualatin, OR 97062 in Washington County. The practice phone is (503) 692-4843.

Dr. Azghadi's primary practice is Meridian Park Radiation Oncolog Center, Inc in Tualatin, Oregon. Dr. Azghadi is also affiliated with John Muir Medical Center, Walnut Creek. The medical group on file is BASS Medical Group. Dmand AI also links Dr. Azghadi to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Azghadi practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Azghadi's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Azghadi is board certified in radiation oncology by the American Board of Radiology. Dr. Azghadi is licensed in California.

Dmand AI lists bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, cervical cancer radiation, colorectal cancer radiation and head & neck cancer radiation among the conditions Dr. Azghadi treats.

CMS data shows 4,545 Medicare services from Dr. Azghadi across 25 procedure codes in 2024, for 180 Medicare patients. Medicare paid $1,274,528 for them. Every service was in an office.

CMS counts 180 Medicare patients who saw Dr. Azghadi in 2024. The largest group is 65 to 74, with 79 patients. 75% of them have cancer, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Azghadi's median patient age at 70, with 67% women.

In 2024, Dr. Azghadi wrote 53 Medicare Part D claims for 26 patients. 83% of them were for generic drugs. CMS names the drug for 41 of them, across 2 drugs with 11 or more claims each, at $906 in total drug cost. In 2020, CMS named 44 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Azghadi for performance year 2024, reported individually. Dr. Azghadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Azghadi as offering telehealth.

Dmand AI links 13 papers to Dr. Azghadi, published from 2012 to 2024. 2012 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Gene Expression Regulation, Developmental and Models, Biological. Dr. Azghadi's most frequent co-authors are Megan Eileen Daly, MD, Brandon Alan Dyer, MD and Peiyee Lee, MD, PhD.

CMS Open Payments shows 328 general payments to Dr. Azghadi from 69 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,050.

Dmand AI lists 2 awards for Dr. Azghadi, most recently Best Abstract Award in 2016.

Dr. Azghadi graduated from UC Davis School of Medicine in 2017. Dr. Azghadi is a member of Alpha Omega Alpha.

Dr. Azghadi is in network with 4 carriers, including Aetna, Humana and CMS Medicare. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.